Table 2.

Treatments according to the line of treatment.

1st line treatment	n = 279 (100%)
PNA	208 (75)
Cladribine	159 (57)
Pentostatin	49 (18)
Other	59 (21)
IFN	40
IFN then cladribine	7
Splenectomy	3
Cladribine + rituximab	2
Pentostatin then cladribine	2
Splenectomy then pentostatin	1
IFN then pentostatin	1
R-CHOP	1
Pentostatin + rituximab	1
Unknown	1
No treatment	12 (4)

2nd line treatment	n = 112 (100%)
PNA	77 (69)
Cladribine	59 (53)
Pentostatin	18 (16)
Other	25 (22)
IFN	11
Rituximab	7
Cladribine + rituximab	3
Pentostatin + rituximab	1
IFN + rituximab	1
IFN then pentostatin	1
Splenectomy	1
No treatment	10 (9)

3rd line treatment	n = 49 (100%)
PNA	29 (59)
Cladribine	12 (24)
Pentostatin	17 (35)
Other	15 (31)
Rituximab	5
Cladribine + rituximab	4
IFN	3
Pentostatin + rituximab	1
Cladribine + IFN	1
Rituximab + bendamustine then vemurafenib	1
No treatment	5 (10)

4th line treatment	n = 16 (100%)
PNA	9 (56)
Cladribine	6 (38)
Pentostatin	3 (18)
Other	7 (44)
IFN	3
Rituximab	2
Pentostatin + rituximab	1
IFN + rituximab	1

5th line treatment	n = 9
PNA	5
Cladribine	3
Pentostatin	2
Other	4
IFN	2
Fludarabine + rituximab	1
R-CHOP	1

6th line treatment	n = 5
PNA	2
Cladribine	1
Pentostatin	1
Other	2
IFN	1
Splenectomy	1
No treatment	1

7th line treatment	n = 4
PNA	1
Cladribine	1
Other	3
IFN	2
R-DHAX then HSCT	1

“then” means that patients received a sequential treatment.

PNA purine analogs, IFN interferon α, R-CHOP rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone, R-DHAX rituximab, dexamethasone, cytarabine, and oxaliplatin, HSCT hematopoietic (allogeneic) stem cell transplantation.